2019
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D'Souza DN, Rees TM. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验. Journal Of Diabetes 2014, 7: 270-278. PMID: 24734891, DOI: 10.1111/1753-0407.12162.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringChinaCross-Over StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Double-Blind MethodFemaleFollow-Up StudiesHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulin AspartInsulin Infusion SystemsInsulin LisproMalePostprandial PeriodPrognosisRisk FactorsConceptsContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseTreatment periodCross-over designBlood glucoseDay 6Insulin aspartInsulin lisproMean total daily insulin doseTotal daily insulin doseTotal hypoglycemia rateDaily insulin dosePrimary efficacy measureType 1 DMMean blood glucoseSubcutaneous insulin infusionType 1 diabetesHypoglycemia ratesInsulin doseRandomized trialsEfficacy measuresSMBG profilesInsulin infusionDay 1Two-treatment
2013
Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming
Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV. Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. Diabetes Technology & Therapeutics 2013, 16: 20-25. PMID: 24367934, PMCID: PMC3887414, DOI: 10.1089/dia.2013.0187.Peer-Reviewed Original Research
2012
Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device
Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes 2012, 14: 168-173. PMID: 23107353, PMCID: PMC3572265, DOI: 10.1111/pedi.12001.Peer-Reviewed Original ResearchConceptsPlasma insulin levelsInsulin actionInsulin levelsAspart insulinRapid-acting insulin analoguesPhysiologic insulin actionClosed-loop insulin deliveryPostprandial glucose excursionsEuglycemic clamp techniqueIp activationTime-action profileType 1 diabetesWarming devicesEuglycemic clamp procedureBolus doseGlucose excursionsPharmacodynamic profileClamp procedurePeak actionInfusion siteBlood flowInsulin analoguesClamp techniqueInsulin absorptionInsulin bolusThe Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injection
2008
Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes Care 2008, 32: 240-244. PMID: 19017777, PMCID: PMC2628686, DOI: 10.2337/dc08-0595.Peer-Reviewed Original ResearchConceptsInsulin pump therapyGlucose infusion rateType 1 diabetesDay 1Day 4Pump therapyInsulin aspartPharmacodynamic parametersInsulin actionInsulin bolusRapid acting analogsEuglycemic clamp procedureExogenous glucose infusionGIR curveEffect of agePharmacodynamic measuresPharmacodynamic characteristicsClamp procedureInfusion siteGlucose infusionInfusion rateInsulin analoguesType 1AspartOverall insulin action